Skip to main content

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Publication ,  Journal Article
Holland, R; Tillett, W; Ogdie, A; Leung, YY; Gladman, DD; Callis Duffin, K; Coates, LC; Mease, PJ; Eder, L; Strand, V; Elmamoun, M; Chau, J ...
Published in: J Rheumatol Suppl
June 2018

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.

Duke Scholars

Published In

J Rheumatol Suppl

DOI

ISSN

0380-0903

Publication Date

June 2018

Volume

94

Start / End Page

17 / 25

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Symptom Assessment
  • Severity of Illness Index
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Outcome Assessment, Health Care
  • Humans
  • Arthritis, Psoriatic
  • Antirheumatic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Holland, R., Tillett, W., Ogdie, A., Leung, Y. Y., Gladman, D. D., Callis Duffin, K., … Orbai, A.-M. (2018). Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. J Rheumatol Suppl, 94, 17–25. https://doi.org/10.3899/jrheum.180142
Holland, Richard, William Tillett, Alexis Ogdie, Ying Y. Leung, Dafna D. Gladman, Kristina Callis Duffin, Laura C. Coates, et al. “Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.J Rheumatol Suppl 94 (June 2018): 17–25. https://doi.org/10.3899/jrheum.180142.
Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai A-M. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. J Rheumatol Suppl. 2018 Jun;94:17–25.

Published In

J Rheumatol Suppl

DOI

ISSN

0380-0903

Publication Date

June 2018

Volume

94

Start / End Page

17 / 25

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Symptom Assessment
  • Severity of Illness Index
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Outcome Assessment, Health Care
  • Humans
  • Arthritis, Psoriatic
  • Antirheumatic Agents